Although the CR rate of ALL in CD19 or CD22 CAR T-cell treatment is as high as 57% to 93%, the relapse rate reaches 14% to 66% (Table 1), which becomes one of the most significant issues limiting CAR T-cell application. Here, CD19 is linked to acute lymphoblastic leukemia.